Vericel to Present at Multiple Upcoming Investor Conferences
March 04 2025 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that the Company will present at the following investor
conferences:
- TD Cowen 45th Annual
Health Care Conference on Wednesday, March 5, 2025
- Canaccord Genuity
2025 Musculoskeletal Conference on Monday, March 10, 2025
- Leerink Partners
2025 Global Healthcare Conference on Wednesday, March 12, 2025
A webcast of the presentations will be available on the Investor
Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the
sports medicine and severe burn care markets. The Company combines
innovations in biology with medical technologies, resulting in a
highly differentiated portfolio of innovative cell therapies and
specialty biologics that repair injuries and restore lives. Vericel
markets three products in the United States. MACI (autologous
cultured chondrocytes on porcine collagen membrane) is an
autologous cellularized scaffold product indicated for the repair
of symptomatic, single or multiple full-thickness cartilage defects
of the knee with or without bone involvement in adults. Epicel
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel
also holds an exclusive license for North American rights to
NexoBrid (anacaulase-bcdb), a biological orphan product containing
proteolytic enzymes, which is indicated for eschar removal in
adults and pediatric patients with deep partial-thickness and/or
full-thickness burns. For more information, please visit
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2025 Vericel
Corporation. All rights reserved.
Investor Contact:Eric Burnsir@vcel.com+1 (734)
418-4411
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2025 to Apr 2025
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2024 to Apr 2025